Quinoline derivatives and quinazoline derivatives

Details Quinoline derivatives and quinazoline derivatives Quinoline derivatives and quinazoline derivatives

2001-07-23

2004-09-28

Berch, Mark L. (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C544S288000, C544S117000, C544S119000, C544S183000, C546S153000

Reexamination Certificate

active

06797823

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to quinoline derivatives and quinazoline derivatives having antitumor activity. More particularly, the present invention relates to quinoline derivatives and quinazoline derivatives that are useful for the treatment of diseases such as tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma.
2. Background Art
WO 97/17329 describes quinoline derivatives and quinazoline derivatives having antitumor activity. WO 97/17329, however, discloses neither the effects of these quinoline derivatives and quinazoline derivatives on cytomorphosis nor the compounds according to the present invention.
SUMMARY OF THE INVENTION
The present inventors have found that a group of quinoline derivatives and quinazoline derivatives has antitumor activity and, at the same time, has no significant effect on cytomorphosis. The activity of increasing the cell size may be regarded as activity of inducing tissue disorders.
An object of the present invention is to provide compounds which have antitumor activity and, at the same time, have no significant effect on cytomorphosis.
According to the present invention, there is provided a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof:
wherein
X and Z each represent CH or N;
R
1
, R
2
, and R
3
, which may be the same or different, represent a hydrogen atom, C
1-6
, alkyl, C
1-6
alkoxy, C
2-6
alkenyl, C
2-6
alkynyl, nitro, or amino, which C
1-6
alkyl, C
1-6
alkoxy, C
2-6
alkenyl, and C
2-6
alkynyl are optionally substituted by a halogen atom; hydroxyl; C
1-4
alkoxy; C
1-4
alkoxycarbonyl; amino on which one or two hydrogen atoms are optionally substituted by C
1-4
alkyl optionally substituted by hydroxyl or C
1-4
alkoxy; group R
12
R
13
N—C(═O)—O— wherein R
12
and R
13
, which may be the same or by different, represent a hydrogen atom or C
1-4
alkyl which alkyl is optionally substituted by hydroxyl or C
1-4
alkoxy; or group R
14
—(S)m- wherein R
14
represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group optionally substituted by C
1-4
alkyl and m is 0 or 1;
R
4
represents a hydrogen atom;
R
5
, R
6
, R
7
, and R
8
, which may be the same or different, represent a hydrogen atom, a halogen atom, C
1-4
alkyl, C
1-4
alkoxy, C
1-4
alkylthio, nitro, or amino, provided that R
5
, R
6
, R
7
, and R
8
do not simultaneously represent a hydrogen atom;
R
9
and R
10
, which may be the same or different, represent a hydrogen atom, C
1-6
alkyl, or C
1-4
alkylcarbonyl, the alkyl portion of which C
1-6
alkyl or C
1-4
alkylcarbonyl is optionally substituted by a halogen atom; C
1-4
alkoxy; amino which is optionally substituted by C
1-4
alkyl optionally substituted by C
1-4
alkoxy; or a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group; and
R
11
represents C
1-6
alkyl, C
2-6
alkenyl, or C
2-6
alkynyl (which C
1-6
alkyl, C
2-6
alkenyl, and C
2-6
alkynyl each are optionally substituted by a halogen atom or C
1-6
alkoxy), or R
15
—(CH
2
)n— wherein n is an integer of 0 to 4 and R
15
represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group which is optionally substituted by a halogen atom, C
1-6
alkyl, or C
1-6
alkoxy and is optionally condensed with other saturated or unsaturated three- to seven-membered carbocyclic ring or heterocyclic ring to form a bicyclic ring.
The compound according to the present invention is useful, for example, for the treatment of tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and solid tumor.


REFERENCES:
patent: 5480883 (1996-01-01), Spada
patent: 6143764 (2000-11-01), Kubo et al.
patent: 2003/0087907 (2003-05-01), Kubo et al.
patent: 0 860 433 (1998-08-01), None
patent: 10-505600 (1998-06-01), None
patent: 11-158149 (1999-06-01), None
patent: WO 200147890 (2001-07-01), None
Ghosh, Acta Crystallographica C57, 76 (2001).
Vollhardt, “Organic Chemistry” (1987), pp. 1179.
Funa, Jikken, Igaku 9(2) 139-143 (1991).

Affiliated with

Also associated with

Rating

Quinoline derivatives and quinazoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinoline derivatives and quinazoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline derivatives and quinazoline derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3226024